Avastin Compounding Does Not Increase Endophthalmitis Risk, Study Says
This article was originally published in The Pink Sheet Daily
Observational cohort data suggest infection risk is lower with off-label use of compounded Avastin than with Genentech's approved ophthalmic treatment, Lucentis, although not statistically significant.
You may also be interested in...
Over two years, serious adverse events occurred at a 40% rate for patients treated with Avastin and at a 32% rate for patients receiving Lucentis, CATT researchers report in an article published in the journal Ophthalmology.
The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.
The request for an interview by the House Select Subcommittee on the Coronavirus Crisis seeks more information on the actions by President Trump and others to influence FDA decisions on HCQ, convalescent plasma, and vaccine decisions.